BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 16138439)

  • 1. Imipenem-cilastatin induced pure white cell aplasia.
    Kalambokis G; Vassou A; Bourantas K; Tsianos EV
    Scand J Infect Dis; 2005; 37(8):619-620. PubMed ID: 16138439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe neutropenia in a patient treated with imipenem/cilastatin.
    Fariñas MC; de Vega T; Garmendia J; González-Macías J
    Eur J Clin Microbiol Infect Dis; 1993 Apr; 12(4):303-4. PubMed ID: 8513823
    [No Abstract]   [Full Text] [Related]  

  • 3. [Imipenem/cilastatin-induced acute thrombocytopenia].
    Alegre Herrera S; Quirós Valera M; Rodríguez Fernández A
    Med Clin (Barc); 2001 Jul; 117(5):197-8. PubMed ID: 11481089
    [No Abstract]   [Full Text] [Related]  

  • 4. Clozapine-induced agranulocytosis: a case report. Immunopathophysiological considerations.
    van de Loosdrecht AA; Faber HJ; Hordijk P; Uges DR; Smit A
    Neth J Med; 1998 Jan; 52(1):26-9. PubMed ID: 9573739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Worsening of myasthenia gravis on treatment with imipenem/cilastatin.
    O'Riordan J; Javed M; Doherty C; Hutchinson M
    J Neurol Neurosurg Psychiatry; 1994 Mar; 57(3):383. PubMed ID: 8158196
    [No Abstract]   [Full Text] [Related]  

  • 6. Vertigo caused by intravenous imipenem/cilastatin.
    Duque A; Altimiras J; García-Cases C; Vidal P
    DICP; 1991 Sep; 25(9):1009. PubMed ID: 1949961
    [No Abstract]   [Full Text] [Related]  

  • 7. Lack of cross-reactivity to meropenem in a patient with an allergy to imipenem-cilastatin.
    Bauer SL; Wall GC; Skoglund KJ; Peters LK
    J Allergy Clin Immunol; 2004 Jan; 113(1):173-5. PubMed ID: 14713926
    [No Abstract]   [Full Text] [Related]  

  • 8. Seizures related to use of imipenem-cilastatin.
    Lane M; Kania D; Rapp RP
    Am J Health Syst Pharm; 1996 Jul; 53(13):1605-6. PubMed ID: 8809285
    [No Abstract]   [Full Text] [Related]  

  • 9. Imipenem/cilastatin treatment of bacterial meningitis in children.
    Wong VK; Wright HT; Ross LA; Mason WH; Inderlied CB; Kim KS
    Pediatr Infect Dis J; 1991 Feb; 10(2):122-5. PubMed ID: 2062603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safe use of imipenem/cilastatin in a neonatal intensive care unit.
    Lee SY; Chow CB
    Acta Paediatr Jpn; 1998 Apr; 40(2):186-7. PubMed ID: 9581316
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of dosage-monitoring system on frequency of seizures associated with imipenem-cilastatin.
    Guglielmo BJ; Jacobs RA
    Am J Health Syst Pharm; 1996 Sep; 53(17):2097-8. PubMed ID: 8870902
    [No Abstract]   [Full Text] [Related]  

  • 12. Imipenem/cilastatin-induced acute eosinophilic pneumonia.
    Foong KS; Lee A; Pekez M; Bin W
    BMJ Case Rep; 2016 Mar; 2016():. PubMed ID: 26944380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of imipenem/cilastatin in neutropenic patients with haematological malignancies.
    Janmohamed RM; Leyland MJ; Kelly J; Farrell I
    J Antimicrob Chemother; 1990 Mar; 25(3):407-12. PubMed ID: 2338419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imipenem-cilastatin-induced psychosis: a case report.
    Ninan J; George GM
    J Med Case Rep; 2016 Apr; 10(1):107. PubMed ID: 27118305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem/cilastatin. European Study Group.
    Norrby SR; Finch RG; Glauser M
    J Antimicrob Chemother; 1993 Jun; 31(6):927-37. PubMed ID: 8360130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of imipenem hypersensitivity reactions in febrile neutropenic bone marrow transplant patients with a history of penicillin allergy.
    McConnell SA; Penzak SR; Warmack TS; Anaissie EJ; Gubbins PO
    Clin Infect Dis; 2000 Dec; 31(6):1512-4. PubMed ID: 11096026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of imipenem/cilastatin with the combination of aztreonam and clindamycin in the treatment of intra-abdominal infections.
    de Groot HG; Hustinx PA; Lampe AS; Oosterwijk WM
    J Antimicrob Chemother; 1993 Sep; 32(3):491-500. PubMed ID: 8262872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group.
    Eklund AE; Nord CE
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():79-85. PubMed ID: 8383657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Imipenem/cilastatin as monotherapy in neutropenic patients with fever].
    Fridrik MA; Wahl G; Grafinger-Witt E; Leisch F
    Wien Med Wochenschr; 1988 Nov; 138(21):548-51. PubMed ID: 3201783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.
    Brismar B; Malmborg AS; Tunevall G; Lindgren V; Bergman L; Mentzing LO; Nyström PO; Anséhn S; Bäckstrand B; Skau T
    J Antimicrob Chemother; 1995 Jan; 35(1):139-48. PubMed ID: 7768761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.